8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Feb 26, 2026·SEC
DexCom, Inc.(DXCM)Earnings, Financials & Key Ratios
DXCM•NASDAQ
34.7× P/E·Price updated Jun 19, 2026
AboutDexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Show more
- Revenue$4.66B+15.6%
- EBITDA$1.16B+42.3%
- Net Income$836M+45.1%
- EPS (Diluted)2.09+47.2%
- Gross Margin60.01%-0.7%
- EBITDA Margin24.96%+23.1%
- Operating Margin19.56%+31.5%
- Net Margin17.94%+25.6%
- ROE34.5%+24.9%
DXCM Key Insights
DexCom, Inc. (DXCM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 29.3%
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 23.1% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 19.3%
- ✓Healthy 5Y average net margin of 13.6%
✗Weaknesses
- ✗Expensive at 10.7x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DXCM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DXCM Price & Volume
DexCom, Inc. (DXCM) stock price & volume — 10-year historical chart
Loading chart...
DXCM Growth Metrics
DexCom, Inc. (DXCM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years27.77%
5 Years19.33%
3 Years17.01%
TTM16.15%
Profit CAGR
10 Years-
5 Years11.12%
3 Years34.83%
TTM73.84%
EPS CAGR
10 Years-
5 Years10.48%
3 Years37.73%
TTM74.63%
Return on Capital
10 Years4%
5 Years13.87%
3 Years17.51%
Last Year23.53%
DXCM Recent Earnings
DexCom, Inc. (DXCM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.56+20.3%
$0.47
Rev
$1.2B+1.5%
$1.2B
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.68+4.6%
$0.65
Rev
$1.3B+0.9%
$1.2B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.61+5.9%
$0.58
Rev
$1.2B+2.2%
$1.2B
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.48+8.2%
$0.44
Rev
$1.2B+2.9%
$1.1B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.56vs $0.47+20.3% | $1.2Bvs $1.2B+1.5% |
| Q1 2026 | Feb 12, 2026 | $0.68vs $0.65+4.6% | $1.3Bvs $1.2B+0.9% |
| Q4 2025 | Oct 30, 2025 | $0.61vs $0.58+5.9% | $1.2Bvs $1.2B+2.2% |
| Q3 2025 | Jul 30, 2025 | $0.48vs $0.44+8.2% | $1.2Bvs $1.1B+2.9% |
Based on last 12 quarters of dataView full earnings history →
DXCM Peer Comparison
DexCom, Inc. (DXCM) competitors in Diabetes care and insulin delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 PODD | 10.23B | 145.76 | 41.89 | 30.73% | 10.44% | 21.38% | 0.69 | |
 TNDM | 1.05B | 15.30 | -5.03 | 7.93% | -9.2% | -68.29% | 2.86 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 PHG | 25.5B | 26.78 | 25.02 | -1.04% | 5.49% | 8.96% | 0.74 | |
 ITGR | 3.13B | 90.96 | 31.47 | 7.57% | 7.67% | 8.23% | 0.80 |
Compare DXCM vs Peers
DexCom, Inc. (DXCM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DXCM Income Statement
DexCom, Inc. (DXCM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 718.5M | 1.03B | 1.48B | 1.93B | 2.45B | 2.91B | 3.62B | 4.03B | 4.66B | 4.82B |
Revenue Growth % | 25.33% | 43.58% | 43.08% | 30.54% | 27.08% | 18.84% | 24.49% | 11.34% | 15.6% | 16.15% |
Cost of Goods Sold | 226.4M | 367.7M | 544.5M | 646.6M | 768M | 1.03B | 1.33B | 1.59B | 1.86B | 1.84B |
COGS % of Revenue | 31.51% | 35.64% | 36.89% | 33.56% | 31.37% | 35.28% | 36.81% | 39.54% | 39.99% | - |
Gross Profit | 492.1M▲ 0% | 663.9M▲ 34.9% | 931.5M▲ 40.3% | 1.28B▲ 37.4% | 1.68B▲ 31.3% | 1.88B▲ 12.1% | 2.29B▲ 21.5% | 2.44B▲ 6.5% | 2.8B▲ 14.7% | 2.98B▲ 0% |
Gross Margin % | 68.49% | 64.36% | 63.11% | 66.44% | 68.63% | 64.72% | 63.19% | 60.46% | 60.01% | 61.84% |
Gross Profit Growth % | 30.05% | 34.91% | 40.31% | 37.42% | 31.28% | 12.06% | 21.55% | 6.52% | 14.74% | - |
Operating Expenses | 534.6M | 850.2M | 789.2M | 980.6M | 1.41B | 1.49B | 1.69B | 1.84B | 1.89B | 1.95B |
OpEx % of Revenue | 74.41% | 82.42% | 53.47% | 50.9% | 57.78% | 51.27% | 46.69% | 45.58% | 40.45% | - |
Selling, General & Admin | 349.2M | 432.8M | 515.7M | 620.7M | 810.5M | 1.01B | 1.19B | 1.29B | 1.29B | 1.33B |
SG&A % of Revenue | 48.6% | 41.95% | 34.94% | 32.22% | 33.1% | 34.63% | 32.73% | 31.88% | 27.69% | - |
Research & Development | 185.4M | 417.4M | 273.5M | 359.9M | 604.2M | 484.2M | 505.8M | 552.4M | 594.9M | 599.2M |
R&D % of Revenue | 25.8% | 40.46% | 18.53% | 18.68% | 24.68% | 16.64% | 13.96% | 13.7% | 12.76% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1000K |
Operating Income | -42.5M▲ 0% | -186.3M▼ 338.4% | 142.3M▲ 176.4% | 299.5M▲ 110.5% | 265.8M▼ 11.3% | 391.2M▲ 47.2% | 597.7M▲ 52.8% | 600M▲ 0.4% | 911.8M▲ 52.0% | 1.03B▲ 0% |
Operating Margin % | -5.92% | -18.06% | 9.64% | 15.54% | 10.86% | 13.44% | 16.5% | 14.88% | 19.56% | 21.45% |
Operating Income Growth % | 33.49% | -338.35% | 176.38% | 110.47% | -11.25% | 47.18% | 52.79% | 0.38% | 51.97% | - |
EBITDA | -26.4M | -157.2M | 191M | 366.6M | 367.7M | 547.1M | 783.7M | 817.7M | 1.16B | 1.23B |
EBITDA Margin % | -3.67% | -15.24% | 12.94% | 19.03% | 15.02% | 18.8% | 21.64% | 20.28% | 24.96% | 25.43% |
EBITDA Growth % | 46.01% | -495.45% | 221.5% | 91.94% | 0.3% | 48.79% | 43.25% | 4.34% | 42.3% | 42.83% |
D&A (Non-Cash Add-back) | 16.1M | 29.1M | 48.7M | 67.1M | 101.9M | 155.9M | 186M | 217.7M | 251.8M | 191.8M |
EBIT | -35.8M | -103.8M | 164.5M | 309.7M | 275.6M | 409.4M | 730.7M | 728M | 911.8M | 778.1M |
Net Interest Income | -6.1M | -20.3M | -33.9M | -68.6M | -17.1M | 5.2M | 114.7M | 115.2M | 94.4M | 70.6M |
Interest Income | 6.7M | 2.4M | 26.4M | 16.1M | 1.7M | 23.8M | 135M | 134.2M | 112.7M | 84.2M |
Interest Expense | 12.8M | 22.7M | 60.3M | 84.7M | 18.8M | 18.6M | 20.3M | 19M | 18.3M | 13.6M |
Other Income/Expense | -6.1M | 59.8M | -38.1M | -74.5M | -9M | -400K | 112.7M | 109M | 176.6M | 170.2M |
Pretax Income | -48.6M▲ 0% | -126.5M▼ 160.3% | 104.2M▲ 182.4% | 225M▲ 115.9% | 256.8M▲ 14.1% | 390.8M▲ 52.2% | 710.4M▲ 81.8% | 709M▼ 0.2% | 1.09B▲ 53.5% | 1.2B▲ 0% |
Pretax Margin % | -6.76% | -12.26% | 7.06% | 11.68% | 10.49% | 13.43% | 19.61% | 17.58% | 23.35% | 24.98% |
Income Tax | 1.6M | 600K | 3.1M | -268.6M | 39.9M | 49.6M | 168.9M | 132.8M | 252.1M | 273.2M |
Effective Tax Rate % | -3.29% | -0.47% | 2.98% | -119.38% | 15.54% | 12.69% | 23.78% | 18.73% | 23.16% | 22.7% |
Net Income | -50.2M▲ 0% | -127.1M▼ 153.2% | 101.1M▲ 179.5% | 493.6M▲ 388.2% | 216.9M▼ 56.1% | 341.2M▲ 57.3% | 541.5M▲ 58.7% | 576.2M▲ 6.4% | 836.3M▲ 45.1% | 930.4M▲ 0% |
Net Margin % | -6.99% | -12.32% | 6.85% | 25.62% | 8.86% | 11.73% | 14.95% | 14.29% | 17.94% | 19.31% |
Net Income Growth % | 23.48% | -153.19% | 179.54% | 388.23% | -56.06% | 57.31% | 58.7% | 6.41% | 45.14% | 73.84% |
Net Income (Continuing) | -50.2M | -127.1M | 101.1M | 493.6M | 216.9M | 341.2M | 541.5M | 576.2M | 836.3M | 930.4M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.15▲ 0% | -0.36▼ 140.0% | 0.27▲ 175.0% | 1.27▲ 370.4% | 0.51▼ 59.8% | 0.80▲ 56.9% | 1.30▲ 62.5% | 1.42▲ 9.2% | 2.09▲ 47.2% | 2.36▲ 0% |
EPS Growth % | 25% | -140% | 175% | 370.37% | -59.84% | 56.86% | 62.5% | 9.23% | 47.18% | 74.63% |
EPS (Basic) | -0.15 | -0.36 | 0.28 | 1.31 | 0.56 | 0.88 | 1.44 | 1.46 | 2.14 | - |
Diluted Shares Outstanding | 345.2M | 352.8M | 369.2M | 390M | 428.8M | 427.5M | 425.5M | 412.7M | 405.5M | 393.6M |
Basic Shares Outstanding | 345.2M | 352.8M | 364.4M | 377.6M | 386.9M | 389.4M | 386M | 404.63M | 390.2M | 385.1M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
DXCM Balance Sheet
DexCom, Inc. (DXCM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 744.7M | 1.7B | 1.97B | 3.42B | 3.68B | 3.67B | 4.43B | 4.3B | 4.03B | 4.33B |
Cash & Short-Term Investments | 548.6M | 1.39B | 1.53B | 2.71B | 2.73B | 2.46B | 2.72B | 2.58B | 2B | 2.42B |
Cash Only | 441.5M | 1.14B | 446.2M | 817.6M | 1.05B | 642.3M | 566.3M | 606.1M | 917.7M | 1.12B |
Short-Term Investments | 107.1M | 248.6M | 1.09B | 1.89B | 1.68B | 1.81B | 2.16B | 1.97B | 1.08B | 1.3B |
Accounts Receivable | 134.3M | 226.7M | 286.3M | 428.5M | 516.6M | 752.2M | 987.5M | 1.03B | 1.29B | 1.09B |
Days Sales Outstanding | 68.22 | 80.21 | 70.8 | 81.18 | 77.01 | 94.35 | 99.51 | 93.54 | 100.99 | 93.28 |
Inventory | 45.2M | 70.7M | 119.8M | 234.7M | 357.3M | 306.7M | 559.6M | 542.6M | 629.1M | 693.6M |
Days Inventory Outstanding | 72.87 | 70.18 | 80.31 | 132.49 | 169.81 | 109.03 | 153.18 | 124.18 | 123.17 | 123.94 |
Other Current Assets | 0 | 0 | 0 | 0 | 27.4M | 37M | 64.5M | 58.3M | 49.2M | 134.3M |
Total Non-Current Assets | 159.4M | 216.5M | 425.6M | 865.7M | 1.25B | 1.72B | 1.84B | 2.18B | 2.31B | 2.3B |
Property, Plant & Equipment | 145.6M | 183.1M | 392.8M | 608.6M | 889.9M | 1.14B | 1.18B | 1.4B | 1.64B | 1.63B |
Fixed Asset Turnover | 4.93x | 5.63x | 3.76x | 3.17x | 2.75x | 2.56x | 3.06x | 2.88x | 2.85x | 3.05x |
Goodwill | 12.1M | 18.7M | 18.6M | 19.3M | 26.5M | 25.7M | 25.2M | 22.8M | 24.2M | 24.2M |
Intangible Assets | 0 | 0 | 0 | 21.4M | 31.5M | 173.3M | 134.5M | 103.4M | 70.8M | 62.6M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 19M | 38.5M | 119.3M | 218M | 550.7M |
Other Non-Current Assets | 1.7M | 14.7M | 14.2M | 0 | 10.5M | 28.1M | 36.5M | 53.7M | 60.7M | 285.9M |
Total Assets | 904.1M▲ 0% | 1.92B▲ 111.9% | 2.4B▲ 25.0% | 4.29B▲ 79.1% | 4.93B▲ 15.0% | 5.39B▲ 9.3% | 6.26B▲ 16.2% | 6.48B▲ 3.5% | 6.34B▼ 2.2% | 6.63B▲ 0% |
Asset Turnover | 0.79x | 0.54x | 0.62x | 0.45x | 0.50x | 0.54x | 0.58x | 0.62x | 0.74x | 0.69x |
Asset Growth % | 124.45% | 111.92% | 25% | 79.14% | 14.98% | 9.29% | 16.19% | 3.51% | -2.23% | 21.82% |
Total Current Liabilities | 138.9M | 222.4M | 360.2M | 614.1M | 720.8M | 1.84B | 1.56B | 2.93B | 2.14B | 2.22B |
Accounts Payable | 46.7M | 75.5M | 102.3M | 163.3M | 189.4M | 237.9M | 276.4M | 345.3M | 344.3M | 0 |
Days Payables Outstanding | 75.29 | 74.95 | 68.58 | 92.18 | 90.01 | 84.58 | 75.66 | 79.03 | 67.41 | 62.92 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 772.6M | 0 | 1.2B | 0 | 20.5M |
Deferred Revenue (Current) | 3.2M | 2.9M | 1.7M | 2.2M | 2.1M | 10.1M | 18.4M | 8M | 7.7M | 16.7M |
Other Current Liabilities | 0 | 0 | 0 | 26.6M | 48.4M | 47.7M | 46.4M | 56.1M | 54.6M | 2.2B |
Current Ratio | 5.36x | 7.64x | 5.47x | 5.58x | 5.11x | 1.99x | 2.84x | 1.47x | 1.88x | 1.95x |
Quick Ratio | 5.04x | 7.32x | 5.13x | 5.19x | 4.62x | 1.83x | 2.48x | 1.28x | 1.59x | 1.64x |
Cash Conversion Cycle | 65.81 | 75.45 | 82.53 | 121.48 | 156.81 | 118.81 | 177.03 | 138.7 | 156.75 | 154.3 |
Total Non-Current Liabilities | 345.8M | 1.03B | 1.15B | 1.85B | 2.17B | 1.42B | 2.64B | 1.45B | 1.45B | 1.45B |
Long-Term Debt | 327.6M | 1.01B | 1.06B | 1.67B | 1.98B | 1.2B | 2.43B | 1.24B | 1.24B | 1.31B |
Capital Lease Obligations | 6.7M | 7.3M | 86.8M | 155.8M | 155.6M | 154.2M | 138.7M | 123.5M | 127.2M | 343.3M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 5.9M | 4.9M | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 11.5M | 12.7M | 5.7M | 26.9M | 11M | 44.8M | 59.6M | 79.9M | 83.3M | 141.8M |
Total Liabilities | 484.7M | 1.25B | 1.51B | 2.46B | 2.89B | 3.26B | 4.2B | 4.38B | 3.59B | 3.68B |
Total Debt | 334.3M | 1.02B | 1.16B | 1.84B | 2.16B | 2.15B | 2.59B | 2.59B | 1.39B | 1.33B |
Net Debt | -107.2M | -119.4M | 713.9M | 1.02B | 1.11B | 1.5B | 2.03B | 1.98B | 472M | 213.1M |
Debt / Equity | 0.80x | 1.53x | 1.31x | 1.01x | 1.06x | 1.01x | 1.25x | 1.23x | 0.51x | 0.45x |
Debt / EBITDA | - | - | 6.07x | 5.02x | 5.87x | 3.92x | 3.31x | 3.16x | 1.19x | 1.09x |
Net Debt / EBITDA | - | - | 3.74x | 2.79x | 3.01x | 2.75x | 2.59x | 2.42x | 0.41x | 0.17x |
Interest Coverage | -2.80x | -4.57x | 2.73x | 3.66x | 14.66x | 22.01x | 36.00x | 38.32x | 49.83x | 57.21x |
Total Equity | 419.4M▲ 0% | 663.3M▲ 58.2% | 882.6M▲ 33.1% | 1.83B▲ 106.9% | 2.04B▲ 11.8% | 2.13B▲ 4.4% | 2.07B▼ 3.0% | 2.1B▲ 1.6% | 2.75B▲ 30.6% | 2.96B▲ 0% |
Equity Growth % | 47.78% | 58.15% | 33.06% | 106.95% | 11.8% | 4.39% | -2.96% | 1.64% | 30.6% | 104.51% |
Book Value per Share | 1.21 | 1.88 | 2.39 | 4.68 | 4.76 | 4.99 | 4.86 | 5.09 | 6.77 | 7.51 |
Total Shareholders' Equity | 419.4M | 663.3M | 882.6M | 1.83B | 2.04B | 2.13B | 2.07B | 2.1B | 2.75B | 2.96B |
Common Stock | 100K | 100K | 100K | 100K | 400K | 400K | 400K | 400K | 400K | 400K |
Retained Earnings | -671.8M | -798.9M | -695.7M | -202.1M | 138.7M | 479.9M | 1.02B | 1.6B | 2.43B | 2.63B |
Treasury Stock | 0 | -100M | -100M | -100M | -206.2M | -595M | -2.45B | -1.58B | -2.08B | 0 |
Accumulated OCI | -2.6M | 1.5M | 2.3M | 3.2M | 500K | -11.6M | -16.7M | -8M | 115M | 106.2M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DXCM Cash Flow Statement
DexCom, Inc. (DXCM) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 92M | 123.2M | 314.5M | 475.6M | 442.5M | 669.5M | 748.5M | 989.5M | 1.44B | 1.78B |
Operating CF Margin % | 12.8% | 11.94% | 21.31% | 24.68% | 18.07% | 23.01% | 20.66% | 24.54% | 30.9% | - |
Operating CF Growth % | 63.7% | 33.91% | 155.28% | 51.22% | -6.96% | 51.3% | 11.8% | 32.2% | 45.6% | 422.73% |
Net Income | -50.2M | -127.1M | 101.1M | 493.6M | 154.7M | 341.2M | 541.5M | 576.2M | 836.3M | 930.4M |
Depreciation & Amortization | 16.1M | 29.1M | 48.7M | 67.1M | 102M | 155.9M | 186M | 217.7M | 251.8M | 258.9M |
Stock-Based Compensation | 106.2M | 101.9M | 102.7M | 119.4M | 113.4M | 126.5M | 150.8M | 170.4M | 159.6M | 168.7M |
Deferred Taxes | 0 | -80.1M | 4.2M | -277.3M | -4.9M | -21.6M | -55M | -43.8M | 182.2M | 188.3M |
Other Non-Cash Items | 17.3M | 240.3M | 51.7M | 93.6M | 209.3M | 39.8M | -78M | -39.8M | -92.6M | -14.3M |
Working Capital Changes | 2.6M | -40.9M | 6.1M | -20.8M | -132M | 27.7M | 3.2M | 108.8M | 103.4M | 250.5M |
Change in Receivables | -31.8M | -93.2M | -60M | -142.3M | -75.5M | -199.9M | -260.1M | -35M | -201.9M | -177.6M |
Change in Inventory | 400K | -25.5M | -49.1M | -114.5M | -112.2M | 49.3M | -252.6M | 12.4M | -63.7M | -4.7M |
Change in Payables | 21.1M | 56.2M | 109M | 194.5M | 58M | 295.1M | 466.5M | 211.7M | 347M | 366.7M |
Cash from Investing | -144.4M | -139.8M | -1.02B | -1.02B | -216.1M | -521.5M | -507.2M | -207.5M | 536M | 137.3M |
Capital Expenditures | -66M | -67.1M | -180M | -199M | -389.2M | -364.8M | -236.6M | -358.8M | -363.5M | -353.1M |
CapEx % of Revenue | 9.19% | 6.5% | 12.2% | 10.33% | 15.9% | 12.54% | 6.53% | 8.9% | 7.8% | 7.33% |
Acquisitions | 0 | -11.3M | 835.2M | 0 | -30.2M | -3.9M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -78.4M | -61.4M | -835.2M | -11.3M | 10.1M | -14.3M | -17.6M | -15.5M | 600K | -400K |
Cash from Financing | 399.1M | 710.4M | 10.7M | 912.1M | 10.4M | -552.5M | -318.6M | -734.8M | -1.69B | -1.72B |
Debt Issued (Net) | 389M | 836.6M | 0 | 906.2M | 0 | 0 | 443.3M | 0 | -1.21B | 0 |
Equity Issued (Net) | 10.1M | -89.2M | 11.9M | 15.3M | 20.3M | -535.2M | -662.1M | -721.8M | -471.9M | -509.2M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -100M | 0 | 0 | 0 | -557.7M | -688.7M | -750M | -500M | -535.8M |
Other Financing | 0 | -37M | -1.2M | -9.4M | -9.9M | -17.3M | -99.8M | -13M | -7M | -1.21B |
Net Change in Cash | 347M▲ 0% | 695.6M▲ 100.5% | -690.7M▼ 199.3% | 371.8M▲ 153.8% | 235.4M▼ 36.7% | -410.3M▼ 274.3% | -75.8M▲ 81.5% | 39.8M▲ 152.5% | 311.8M▲ 683.4% | 212.3M▲ 0% |
Free Cash Flow | 26M▲ 0% | 56.1M▲ 115.8% | 134.5M▲ 139.8% | 276.6M▲ 105.7% | 53.3M▼ 80.7% | 304.7M▲ 471.7% | 511.9M▲ 68.0% | 630.7M▲ 23.2% | 1.08B▲ 70.8% | 1.43B▲ 0% |
FCF Margin % | 3.62% | 5.44% | 9.11% | 14.36% | 2.18% | 10.47% | 14.13% | 15.64% | 23.11% | 29.67% |
FCF Growth % | 5100% | 115.77% | 139.75% | 105.65% | -80.73% | 471.67% | 68% | 23.21% | 70.79% | 148.5% |
FCF per Share | 0.08 | 0.16 | 0.36 | 0.71 | 0.12 | 0.71 | 1.20 | 1.53 | 2.66 | 3.63 |
FCF Conversion (FCF/Net Income) | -1.83x | -0.97x | 3.11x | 0.96x | 2.04x | 1.96x | 1.38x | 1.72x | 1.72x | 1.54x |
Interest Paid | 2.4M | 3.6M | 10.4M | 10.6M | 11.6M | 12.2M | 12.4M | 11.4M | 11.4M | 0 |
Taxes Paid | 1.4M | 2.3M | 4.8M | 3.6M | 16.8M | 114.2M | 212.3M | 198M | 94.4M | 0 |
DXCM Key Ratios
DexCom, Inc. (DXCM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -14.28% | -23.48% | 13.08% | 36.44% | 11.21% | 16.35% | 25.78% | 27.63% | 34.5% | 33.83% |
Return on Invested Capital (ROIC) | -12.54% | -32.64% | 9.97% | 10.11% | 6.65% | 8.65% | 11.6% | 11% | 18.73% | 22.39% |
Gross Margin | 68.49% | 64.36% | 63.11% | 66.44% | 68.63% | 64.72% | 63.19% | 60.46% | 60.01% | 61.84% |
Net Margin | -6.99% | -12.32% | 6.85% | 25.62% | 8.86% | 11.73% | 14.95% | 14.29% | 17.94% | 19.31% |
Debt / Equity | 0.80x | 1.53x | 1.31x | 1.01x | 1.06x | 1.01x | 1.25x | 1.23x | 0.51x | 0.45x |
Interest Coverage | -2.80x | -4.57x | 2.73x | 3.66x | 14.66x | 22.01x | 36.00x | 38.32x | 49.83x | 57.21x |
FCF Conversion | -1.83x | -0.97x | 3.11x | 0.96x | 2.04x | 1.96x | 1.38x | 1.72x | 1.72x | 1.54x |
Revenue Growth | 25.33% | 43.58% | 43.08% | 30.54% | 27.08% | 18.84% | 24.49% | 11.34% | 15.6% | 16.15% |
Related:DXCM Dividend History·DXCM Revenue History·DXCM Price History·DXCM P/E History·DXCM Financial Ratios·DXCM Institutional Holders
DXCM SEC Filings & Documents
DexCom, Inc. (DXCM) SEC filings — annual & quarterly reports (10-K, 10-Q)
DXCM Frequently Asked Questions
DexCom, Inc. (DXCM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
DexCom, Inc. (DXCM) reported $4.82B in revenue for fiscal year 2025.
DexCom, Inc. (DXCM) grew revenue by 15.6% over the past year. This is strong growth.
Yes, DexCom, Inc. (DXCM) is profitable, generating $930.4M in net income for fiscal year 2025 (17.9% net margin).
Dividend & Returns
DexCom, Inc. (DXCM) has a return on equity (ROE) of 34.5%. This is excellent, indicating efficient use of shareholder capital.
DexCom, Inc. (DXCM) generated $1.43B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.